Replimune Group (NASDAQ:REPL) Price Target Raised to $6.00 at Wedbush

Replimune Group (NASDAQ:REPL) had its target price lifted by Wedbush from $2.00 to $6.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Wedbush’s price objective would indicate a potential downside of 34.61% from the stock’s current price.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Piper Sandler lowered shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday, April 10th. Weiss Ratings upgraded shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Jefferies Financial Group restated a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Finally, BMO Capital Markets lowered shares of Replimune Group from a “market perform” rating to an “underperform” rating in a research report on Monday, April 13th. Seven equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, Replimune Group has an average rating of “Reduce” and an average price target of $4.88.

Replimune Group Price Performance

Shares of REPL traded up $0.49 during mid-day trading on Monday, reaching $9.18. 5,288,154 shares of the stock traded hands, compared to its average volume of 4,778,363. The firm has a fifty day moving average price of $4.88 and a 200 day moving average price of $7.25. The company has a market cap of $757.66 million, a price-to-earnings ratio of -2.68 and a beta of 0.88. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the completion of the sale, the insider directly owned 151,588 shares in the company, valued at $1,214,219.88. This represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Several institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its position in Replimune Group by 10.3% during the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock valued at $157,000 after buying an additional 1,505 shares during the period. JPMorgan Chase & Co. boosted its position in Replimune Group by 4.7% during the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock valued at $159,000 after buying an additional 1,712 shares during the period. Ballentine Partners LLC boosted its position in Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock valued at $230,000 after buying an additional 1,721 shares during the period. BNP Paribas Financial Markets boosted its position in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after buying an additional 1,879 shares during the period. Finally, NEOS Investment Management LLC boosted its position in Replimune Group by 5.0% during the third quarter. NEOS Investment Management LLC now owns 42,966 shares of the company’s stock valued at $180,000 after buying an additional 2,060 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.